Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 58
Filtrer
1.
Ther Apher Dial ; 28(4): 557-571, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38499495

RÉSUMÉ

INTRODUCTION: Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis. METHODS: A systematic literature search through October 2023 and a meta-analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included. RESULTS: Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo. CONCLUSION: Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.


Sujet(s)
Calcimimétiques , Calcium , Hyperparathyroïdie secondaire , Phosphates , Essais contrôlés randomisés comme sujet , Dialyse rénale , Hyperparathyroïdie secondaire/traitement médicamenteux , Hyperparathyroïdie secondaire/étiologie , Humains , Calcimimétiques/usage thérapeutique , Dialyse rénale/méthodes , Calcium/sang , Phosphates/sang
2.
Clin Exp Nephrol ; 28(4): 307-315, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38141089

RÉSUMÉ

BACKGROUND: In patients with chronic kidney disease (CKD), the incidence of cardiovascular disease (CVD) increases with disease progression. CVD screening tests in those with CKD were researched to determine whether abnormalities observed in electrocardiography (ECG) and ultrasonic echocardiography (UCG) were risk factors associated with the development of CVD. METHODS: This study included 604 patients with CKD G4 and G5, for whom both ECG and UCG were performed. They were divided into four groups: those without ECG- and UCG-indicated abnormalities (group A, n = 333), with only ECG abnormalities (group B, n = 106), with only UCG abnormalities (group C, n = 75), and with both ECG and UCG abnormalities (group D, n = 90). Multivariate analysis using Cox regression analysis of the occurrence of CVD was performed during a follow-up period. RESULTS: During the observation period, 124 patients had clinical events. Among them, 45 patients (13.5%) were in Group A, 25 patients (23.6%) in Group B, 19 patients (25.3%) in Group C, and 35 patients (38.9%) in Group D, respectively. CVD event occurrence was highest in Group D. The results of the multivariate analysis also showed that the CVD event rates were significantly higher in Group C (HR: 2.96, P = < .001) and D (HR: 4.22, P < .001) than in Group A. CONCLUSION: In patients with advanced CKD, there was a significant correlation of ECG and UCG abnormalities with CVD events. Additionally, those having both types of abnormalities may have a higher risk of coronary artery disease than other groups.


Sujet(s)
Maladies cardiovasculaires , Insuffisance rénale chronique , Humains , Maladies cardiovasculaires/diagnostic , Maladies cardiovasculaires/épidémiologie , Maladies cardiovasculaires/étiologie , Science des ultrasons , Électrocardiographie/effets indésirables , Échocardiographie/effets indésirables , Facteurs de risque , Insuffisance rénale chronique/complications
3.
Mol Genet Metab ; 139(4): 107634, 2023 08.
Article de Anglais | MEDLINE | ID: mdl-37406430

RÉSUMÉ

BACKGROUND: Fabry disease (FD) is an inherited disorder that causes organ dysfunction. However, only a few studies have reported on bone mineral density (BMD) in FD patients, and the relationship between BMD and clinical factors such as globotriaosylsphingosine (lyso-Gb3) remains unclear. Therefore, the current study sought to investigate BMD in FD patients, the relationship between BMD and lyso-Gb3, and the effects of enzyme replacement therapy (ERT) on changes in BMD and lyso-Gb3. METHODS: This single-center, observational study included 15 patients who visited our facility for FD between January 2008 and June 2021. We assessed BMD and clinical characteristics in study patients, including plasma lyso-Gb3 levels, and examined the relationship between BMD and plasma lyso-Gb3 levels, and changes in BMD after starting ERT. RESULTS: Male patients' BMD had reduced, whereas female patients' BMD was preserved. Male patients had significantly higher plasma lyso-Gb3 levels than female patients. Moreover, plasma lyso-Gb3 levels were found to be significantly related to the lumbar spine and femoral BMD. These were strongly linked with plasma lyso-Gb3 levels in male patients, whereas no strong link was observed in female patients. Furthermore, BMD significantly increased only in male patients although plasma lyso-Gb3 levels significantly decreased by ERT in all patients. CONCLUSION: BMD decreased possibly due to Gb3 accumulation, and ERT could increase BMD in male FD patients.


Sujet(s)
Maladie de Fabry , Humains , Mâle , Femelle , Maladie de Fabry/thérapie , alpha-Galactosidase/usage thérapeutique , Thérapie enzymatique substitutive , Densité osseuse , Sphingolipides , Glycolipides , Patients
4.
Clin Exp Nephrol ; 27(7): 593-602, 2023 Jul.
Article de Anglais | MEDLINE | ID: mdl-37140734

RÉSUMÉ

BACKGROUND: Astragalus root is a commonly used herb in traditional Chinese medicine. Although renoprotective effects have been reported in some clinical and experimental studies, the details remain unknown. METHODS: We used 5/6 nephrectomized rats as chronic kidney disease (CKD) models. At 10 weeks, they were divided into four groups, namely, CKD, low-dose astragalus (AR400), high-dose astragalus (AR800), and sham groups. At 14 weeks, they were sacrificed for the evaluation of blood, urine, mRNA expression in the kidney, and renal histopathology. RESULTS: Kidney dysfunction was significantly improved following astragalus administration (creatinine clearance: sham group; 3.8 ± 0.3 mL/min, CKD group; 1.5 ± 0.1 mL/min, AR400 group; 2.5 ± 0.3 mL/min, AR800 group; 2.7 ± 0.1 mL/min). Blood pressure, urinary albumin, and urinary NGAL levels were significantly lower in the astragalus-treated groups than those in the CKD group. Excretion of urinary 8-OHdG, an oxidative stress marker, and intrarenal oxidative stress were lower in the astragalus-treated groups than those in the CKD group. Furthermore, the mRNA expression of NADPH p22 phox, NADPH p47 phox, Nox4, renin, angiotensin II type 1 receptor, and angiotensinogen in the kidney was lower in the astragalus-treated groups compared with the CKD group. CONCLUSION: This study suggests that astragalus root slowed CKD progression, possibly through the suppression of oxidative stress and the renin-angiotensin system.


Sujet(s)
Rein , Insuffisance rénale chronique , Rats , Animaux , NADP/métabolisme , NADP/pharmacologie , NADP/usage thérapeutique , Rein/anatomopathologie , Rénine , Système rénine-angiotensine , ARN messager/métabolisme
5.
J Atheroscler Thromb ; 30(11): 1568-1579, 2023 Nov 01.
Article de Anglais | MEDLINE | ID: mdl-36990726

RÉSUMÉ

AIMS: Serum phosphate control is crucial for the progression of vascular and valvular calcifications. Strict phosphate control is recently suggested; however, there is a lack of convincing evidence. Therefore, we explored the effects of strict phosphate control on vascular and valvular calcifications in incident patients undergoing hemodialysis. METHODS: A total of 64 patients undergoing hemodialysis from our previous randomized controlled trial were included in this study. Coronary artery calcification score (CACS) and cardiac valvular calcification score (CVCS) were evaluated using computed tomography and ultrasound cardiography at baseline and 18 months after the initiation of hemodialysis. The absolute changes in CACS (ΔCACS) and CVCS (ΔCVCS) and the percent change in CACS (%ΔCACS) and CVCS (%ΔCVCS) were calculated. Serum phosphate level was measured at 6, 12, and 18 months after the initiation of hemodialysis. Moreover, phosphate control status was evaluated using the area under the curve (AUC) by the amount of time spent with a serum phosphate level of ≥ 4.5 mg/dL and the extent to which this threshold exceeded over the observation period. RESULTS: ΔCACS, %ΔCACS, ΔCVCS, and %ΔCVCS were significantly lower in the low AUC group than in the high AUC group. ΔCACS and %ΔCACS were also significantly lower. ΔCVCS and %ΔCVCS tended to be lower in patients whose serum phosphate level never exceeded 4.5 mg/dL than in those whose serum phosphate level continuously exceeded 4.5 mg/dL. AUC significantly correlated with ΔCACS and ΔCVCS. CONCLUSION: Consistently strict phosphate control may slow the progression of coronary and valvular calcifications in incident patients undergoing hemodialysis.


Sujet(s)
Calcinose , Maladie des artères coronaires , Calcification vasculaire , Humains , Phosphates , Dialyse rénale/effets indésirables , Tomodensitométrie , Calcification vasculaire/étiologie
6.
Front Endocrinol (Lausanne) ; 14: 1276664, 2023.
Article de Anglais | MEDLINE | ID: mdl-38174329

RÉSUMÉ

Background: Whether fibroblast growth factor 23 (FGF23) directly induces left ventricular hypertrophy (LVH) remains controversial. Recent studies showed an association between FGF23 and the renin-angiotensin-aldosterone system (RAAS). The aim of this study was to investigate changes in FGF23 levels and RAAS parameters and their influences on LVH. Methods: In the first experiment, male C57BL/6J mice were divided into sham and transverse aortic constriction (TAC) groups. The TAC group underwent TAC at 8 weeks of age. At 1, 2, 3, and 4 weeks after TAC, the mice were sacrificed, and blood and urine samples were obtained. Cardiac expressions of FGF23 and RAAS-related factors were evaluated, and cardiac histological analyses were performed. In the second experiment, the sham and TAC groups were treated with vehicle, angiotensin-converting enzyme (ACE) inhibitor, or FGF receptor 4 (FGFR4) inhibitor and then evaluated in the same way as in the first experiment. Results: In the early stage of LVH without chronic kidney disease, serum FGF23 levels did not change but cardiac FGF23 expression significantly increased along with LVH progression. Moreover, serum aldosterone and cardiac ACE levels were significantly elevated, and cardiac ACE2 levels were significantly decreased. ACE inhibitor did not change serum FGF23 levels but significantly decreased cardiac FGF23 levels with improvements in LVH and RAAS-related factors, while FGFR4 inhibitor did not change the values. Conclusions: Not serum FGF23 but cardiac FGF23 levels and RAAS parameters significantly changed in the early stage of LVH without chronic kidney disease. RAAS blockade might be more crucial than FGF23 blockade for preventing LVH progression in this condition.


Sujet(s)
Hypertrophie ventriculaire gauche , Insuffisance rénale chronique , Animaux , Mâle , Souris , Inhibiteurs de l'enzyme de conversion de l'angiotensine/pharmacologie , Inhibiteurs de l'enzyme de conversion de l'angiotensine/usage thérapeutique , Facteur-23 de croissance des fibroblastes , Facteurs de croissance fibroblastique/métabolisme , Hypertrophie ventriculaire gauche/anatomopathologie , Souris de lignée C57BL , Myocytes cardiaques/métabolisme , Insuffisance rénale chronique/anatomopathologie , Système rénine-angiotensine
7.
BMC Nephrol ; 23(1): 128, 2022 04 02.
Article de Anglais | MEDLINE | ID: mdl-35366840

RÉSUMÉ

BACKGROUND: Nephrotic syndrome (NS) results in massive proteinuria and hypoalbuminemia, which are responsible for a compensatory increase in protein synthesis in the liver. Serum cholinesterase (ChE) also increases in NS. However, its clinical value is not fully elucidated. METHODS: In this study, 184 patients with NS who underwent kidney biopsy were included. The patients were divided into two groups according to serum ChE levels, as follows: hypercholinesterasemia (HC) and non-hypercholinesterasemia (NHC) groups. The clinical factors were compared between the two groups. RESULTS: The HC group had significantly more severe proteinuria and higher prevalence of high selective proteinuria than the NHC group. Furthermore, the prevalence of minimal change nephrotic syndrome (MCNS) was significantly higher in the HC group than that in the NHC group. Multivariate analysis revealed that the severity of proteinuria and MCNS were significantly associated with HC. CONCLUSION: In this study, HC in NS was associated with the severity of proteinuria and MCNS, and could help clinicians predict the histological diagnosis of NS.


Sujet(s)
Hypoalbuminémie , Néphrose lipoïdique , Syndrome néphrotique , Cholinesterases , Humains , Néphrose lipoïdique/complications , Syndrome néphrotique/complications , Protéinurie/complications
8.
BMC Nephrol ; 23(1): 153, 2022 04 18.
Article de Anglais | MEDLINE | ID: mdl-35436909

RÉSUMÉ

BACKGROUND: Steroid pulse (SP) therapy is one of the immunosuppressive therapies for immunoglobulin A nephropathy (IgAN). Although there are various protocols of SP therapy in IgAN, the intermittent SP (ISP) and consecutive SP (CSP) protocols are prevalently performed in clinical settings. However, there is a lack of evidence of comparisons of the effects on IgAN between these two protocols. METHODS: A total of 189 patients with IgAN who had received SP therapy were included in this study. They were divided into two groups according to the SP protocols into the intermittent SP (ISP) or consecutive SP (CSP) group as follows: ISP; three-times SP therapy in alternate months, CSP; three-times SP therapy in three consecutive weeks. Kidney function, remission of urinary findings, and side effects of SP therapy were compared between the two groups. The observational period was 12 months after the initiation of SP therapy. RESULTS: There was no significant difference in kidney function between the two groups during the observational period. The remission rate of proteinuria and hematuria at 12 months also did not significantly differ between the two groups. Furthermore, even after the adjustment of clinical characteristics using propensity score matching, the remission rate of proteinuria and hematuria at 12 months was similar between the two groups. At 2 months, the remission rate of proteinuria was significantly higher in the CSP group than in the ISP group. There were no critical side effects in both groups. CONCLUSION: The effects of SP therapy on IgAN were similar between the ISP and CSP group at 12 months although CSP therapy could remit proteinuria faster than ISP therapy.


Sujet(s)
Glomérulonéphrite à dépôts d'IgA , Amygdalectomie , Hématurie/traitement médicamenteux , Humains , Méthylprednisolone/usage thérapeutique , Études observationnelles comme sujet , Protéinurie/induit chimiquement , Protéinurie/traitement médicamenteux , Études rétrospectives
9.
Ther Apher Dial ; 26(6): 1187-1192, 2022 Dec.
Article de Anglais | MEDLINE | ID: mdl-35261182

RÉSUMÉ

Fabry disease (FD) manifests decreased α-galactosidase A (α-Gal A) activity and multiorgan damage. There are some undiagnosed cases of the condition among patients on dialysis. The prevalence of FD may also vary with the region. Among 227 male patients undergoing maintenance hemodialysis in Awaji Island, a remote island in Japan, 201 (88.5%) were included in this study. Patients with α-Gal A activity <5.0 pmol/h/disk proceeded to secondary screening. Patients with positive secondary screening underwent further genetic analysis. The number of patients with a family history of cardiac, cerebrovascular, and kidney diseases was 31 (15.4%), 23 (11.4%), and 31 (15.4%) patients, respectively. Although three patients (1.5%) had low α-Gal A activity, none of them was positive in the secondary screening. We could not identify any male hemodialysis patient with FD in Awaji Island, even though some patients had a family history of kidney and cardiovascular diseases.


Sujet(s)
Maladie de Fabry , Maladies du rein , Humains , Mâle , Maladie de Fabry/diagnostic , Maladie de Fabry/épidémiologie , Maladie de Fabry/complications , Dialyse rénale , alpha-Galactosidase/génétique , Rein , Maladies du rein/complications
10.
J Endocr Soc ; 6(2): bvab187, 2022 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-35047715

RÉSUMÉ

Serum fibroblast growth factor 23 (FGF23) levels and the renin-angiotensin-aldosterone system (RAAS) are elevated in chronic kidney disease (CKD) patients, and their association with left ventricular hypertrophy (LVH) has been reported. However, whether the FGF23 elevation is the cause or result of LVH remains unclear. At 10 weeks, male C57BL/6J mice were divided into 4 groups: sham, CKD (5/6 nephrectomy), LVH (transaortic constriction), and CKD/LVH group. At 16 weeks, the mice were euthanized, and blood and urine, cardiac expressions of FGF23 and RAAS-related factors, and cardiac histological analyses were performed. Heart weight, serum FGF23 levels, and cardiac expression of FGF23 and RAAS-related factors, except for angiotensin-converting enzyme 2, were more increased in the CKD/LVH group compared to the other groups. A significant correlation between LVH and cardiac expressions of FGF23 and RAAS-related factors was observed. Furthermore, there was a significantly close correlation of the cardiac expression of FGF23 with LVH and RAAS-related factors. The coexisting CKD and LVH increased serum and cardiac FGF23 and RAAS-related factors, and there was a significant correlation between them. A close correlation of cardiac, but not serum FGF23, with LVH and RAAS suggests that local FGF23 levels may be associated with LVH and RAAS activation.

11.
J Atheroscler Thromb ; 29(11): 1646-1654, 2022 Nov 01.
Article de Anglais | MEDLINE | ID: mdl-35013022

RÉSUMÉ

AIM: Acute kidney injury (AKI) is an important clinical issue in the diagnosis and treatment of cardiovascular diseases. The association between pretreatment by statins and the occurrence of AKI in patients with peripheral arterial diseases (PAD) remains unclear. Therefore, we examined the association between statin therapy and the occurrence of AKI in patients with PAD. METHODS: We retrospectively analyzed data from the endovascular treatment (EVT) database in our hospital. A total of 295 patients who underwent angiography and/or intervention for PAD between October 2011 and March 2016 were enrolled and divided into two groups: those without statins (control group; N=157) and those with statins (statin group; N=138) for at least 1 month before admission. We examined the occurrence of AKI and its related factors in these patients. RESULTS: The serum creatinine levels, dose of contrast medium, use of a renin-angiotensin system inhibitor, smoking habit, and blood pressure were similar in both groups. The statin group had more diabetes patients, had patients who were significantly younger, had patients with a higher body mass index (BMI), and had patients with lower low-density lipoprotein cholesterol than the control group. With regard to the occurrence of AKI, there was a significantly lower incidence in the statin group compared with the control group (5% vs. 16%, p<0.05). The result of the multivariate analysis indicated that statin therapy was significantly correlated with lower occurrence rates of AKI (p<0.05). CONCLUSIONS: Our study suggests that statin therapy might prevent the occurrence of AKI after angiography and/or intervention for PAD.


Sujet(s)
Atteinte rénale aigüe , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase , Maladie artérielle périphérique , Humains , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/effets indésirables , Études rétrospectives , Atteinte rénale aigüe/induit chimiquement , Atteinte rénale aigüe/épidémiologie , Produits de contraste , Maladie artérielle périphérique/épidémiologie , Facteurs de risque
12.
Clin Exp Nephrol ; 25(11): 1224-1230, 2021 Nov.
Article de Anglais | MEDLINE | ID: mdl-34128148

RÉSUMÉ

BACKGROUND: Fabry disease is an X-linked inherited lysosomal storage disorder caused by mutations in the gene encoding α-galactosidase A. Males are usually severely affected, while females have a wide range of disease severity. This variability has been assumed to be derived from organ-dependent skewed X-chromosome inactivation (XCI) patterns in each female patient. Previous studies examined this correlation using the classical methylation-dependent method; however, conflicting results were obtained. This study was established to ascertain the existence of skewed XCI in nine females with heterozygous pathogenic variants in the GLA gene and its relationship to the phenotypes. METHODS: We present five female patients from one family and four individual female patients with Fabry disease. In all cases, heterozygous pathogenic variants in the GLA gene were detected. The X-chromosome inactivation patterns in peripheral blood leukocytes and cells of urine sediment were determined by both classical methylation-dependent HUMARA assay and ultra-deep RNA sequencing. Fabry Stabilization Index was used to determine the clinical severity. RESULTS: Skewed XCI resulting in predominant inactivation of the normal allele was observed only in one individual case with low ⍺-galactosidase A activity. In the remaining cases, no skewing was observed, even in the case with the highest total severity score (99.2%). CONCLUSION: We conclude that skewed XCI could not explain the severity of female Fabry disease and is not the main factor in the onset of various clinical symptoms in females with Fabry disease.


Sujet(s)
Chromosomes X humains/génétique , Maladie de Fabry/génétique , Inactivation du chromosome X , alpha-Galactosidase/génétique , Adulte , Sujet âgé , Méthylation de l'ADN , Maladie de Fabry/sang , Maladie de Fabry/urine , Femelle , Hétérozygote , Humains , Agranulocytes , Adulte d'âge moyen , Analyse de séquence d'ARN , Indice de gravité de la maladie
13.
Clin Kidney J ; 14(1): 325-331, 2021 Jan.
Article de Anglais | MEDLINE | ID: mdl-33564435

RÉSUMÉ

BACKGROUND: Within the class of tyrosine kinase inhibitors (TKIs), which are used for the treatment of numerous advanced cancers, lenvatinib is associated with a higher prevalence of hypertension (HT) compared with other TKIs. In this study, we investigated the effect of lenvatinib on blood pressure (BP) and associated factors. METHODS: This single-centre, retrospective observational study included 25 consecutive patients treated with lenvatinib for unresectable hepatocellular carcinoma from April 2018 to December 2018 at the study institution. We assessed changes in BP using ambulatory BP monitoring, urinary sodium excretion, kidney function, use of antihypertensive agents and diuretics, and fluid retention following treatment initiation with lenvatinib. RESULTS: At 1 week after treatment initiation, the mean BP and the percentage of patients with riser pattern significantly increased compared with those at the baseline. Although there were no significant changes at 1 week, urinary sodium excretion (153.4 ± 51.7 and 112.5 ± 65.0 mEq/day at 1 and 3 weeks, respectively, P < 0.05) and estimated glomerular filtration rate significantly decreased and the number of patients with fluid retention increased at 3 weeks. Furthermore, patients with fluid retention had significantly higher BP or required more intensive BP treatment compared with those without fluid retention. CONCLUSIONS: Lenvatinib might lead to HT without fluid retention soon after the initiation of treatment, subsequently leading to a reduction in urinary sodium excretion, thereby contributing to a rise in BP by fluid retention.

14.
J Bone Miner Metab ; 39(2): 230-236, 2021 Mar.
Article de Anglais | MEDLINE | ID: mdl-32920706

RÉSUMÉ

INTRODUCTION: Hyperparathyroidism (HPT) is associated with mortality and cardiovascular disease (CVD) in dialysis patients. However, its mechanism is still unclear. It is suspected that parathyroid hormone (PTH) is associated with the renin-angiotensin-aldosterone system (RAAS) as a possible mechanism. Thus, we examined their hormonal interaction in hemodialysis patients with secondary HPT. MATERIALS AND METHODS: Seventeen hemodialysis patients with HPT were included. All patients underwent total parathyroidectomy (PTx). Serum intact PTH (iPTH), calcium and phosphate levels, plasma renin activity (PRA), and plasma aldosterone levels (ALD) were measured pre- and post-PTx. RESULTS: Pre-serum iPTH tended to be correlated with pre-PRA and were significantly correlated with pre-ALD (pre-PRA: r = 0.44, p = 0.07, pre-ALD: r = 0.49, p < 0.05). With the reduction in serum iPTH after PTx, PRA and ALD significantly decreased after PTx. Additionally, the change in serum iPTH tended to be correlated with the changes in PRA and ALD (PRA; r = 0.46, p = 0.05, ALD; r = 0.45, p = 0.06). CONCLUSION: Our results suggest that PTH could be interrelated with RAAS in hemodialysis patients with secondary HPT.


Sujet(s)
Hyperparathyroïdie secondaire/sang , Hormone parathyroïdienne/sang , Dialyse rénale , Système rénine-angiotensine , Pression sanguine , Liquides biologiques/métabolisme , Calcium/sang , Ostéodystrophie rénale/sang , Femelle , Humains , Hyperparathyroïdie secondaire/chirurgie , Mâle , Adulte d'âge moyen , Parathyroïdectomie , Potassium/sang
15.
J Bone Miner Metab ; 39(3): 439-445, 2021 May.
Article de Anglais | MEDLINE | ID: mdl-33141340

RÉSUMÉ

INTRODUCTION: Very few studies have been performed to evaluate both the severity and site of aortic calcification (AC) in both end-stage kidney disease (ESKD) and diabetes mellitus (DM). The purpose of our study was to examine the utility of a newly developed three-dimensional (3D) visualization and quantification method compared with other methods to evaluate vascular calcification in ESKD patients with and without DM. MATERIALS AND METHODS: Fifty patients with ESKD before initiating hemodialysis at our hospital were included in the present study. They were divided into the two groups, depending on the presence or absence of DM: Control group (n = 31) and DM group (n = 19). The volume and site of AC were evaluated via computed tomography (CT) scan using a 3D visualization and quantification method. RESULTS: Total calcification volume was significantly greater in the DM group than in the Control group. Calcification volume in the descending and abdominal aortas was greater in the DM group compared to the Control group. There were no significant differences in calcification volume in the aortic root, ascending aorta, and aortic arch. Calcification volume of the whole aorta, the descending aorta, and the abdominal aorta were each significantly correlated with age, diastolic blood pressure and pulse pressure. CONCLUSION: This study using a 3D visualization and quantification method demonstrated that AC was more severe and occurred more frequently in the abdominal aorta in ESKD patients with DM compared to those without DM. This method would enable us to precisely evaluate the volume and distribution of AC.


Sujet(s)
Aorte abdominale/anatomopathologie , Imagerie tridimensionnelle , Défaillance rénale chronique/complications , Défaillance rénale chronique/imagerie diagnostique , Calcification vasculaire/complications , Calcification vasculaire/imagerie diagnostique , Aorte abdominale/imagerie diagnostique , Vaisseaux coronaires/imagerie diagnostique , Vaisseaux coronaires/anatomopathologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Tomodensitométrie
16.
Sci Rep ; 10(1): 20708, 2020 11 26.
Article de Anglais | MEDLINE | ID: mdl-33244056

RÉSUMÉ

Vascular calcification (VC) is a common complication in patients with chronic kidney disease (CKD). Particularly, CKD patients with diabetes mellitus (DM) develop severe VC. Specific mechanisms of VC remain unclear; this study aimed to investigate them in the context of coexisting CKD and DM, mainly regarding oxidative stress. Sprague Dawley rats were randomly divided into six groups as follows: control rats (Control), 5/6 nephrectomized rats (CKD), streptozotocin-injected rats (DM), 5/6 nephrectomized and streptozotocin-injected rats (CKD + DM), CKD + DM rats treated with insulin (CKD + DM + INS), and CKD + DM rats treated with antioxidant apocynin (CKD + DM + APO). At 18 weeks old, the rats were sacrificed for analysis. Compared to the control, DM and CKD groups, calcification of aortas significantly increased in the CKD + DM group. Oxidative stress and osteoblast differentiation-related markers considerably increased in the CKD + DM group compared with the other groups. Moreover, apocynin considerably reduced oxidative stress, osteoblast differentiation-related markers, and aortic calcification despite high blood glucose levels. Our data indicate that coexisting CKD and DM hasten VC primarily through an increase in oxidative stress; anti-oxidative therapy may prevent the VC progression.


Sujet(s)
Diabète/anatomopathologie , Stress oxydatif/physiologie , Insuffisance rénale chronique/anatomopathologie , Calcification vasculaire/anatomopathologie , Animaux , Antioxydants/métabolisme , Marqueurs biologiques/métabolisme , Glycémie/métabolisme , Différenciation cellulaire/physiologie , Diabète/induit chimiquement , Diabète/métabolisme , Évolution de la maladie , Mâle , Ostéoblastes/métabolisme , Ostéoblastes/anatomopathologie , Rats , Rat Sprague-Dawley , Insuffisance rénale chronique/métabolisme , Streptozocine/pharmacologie , Calcification vasculaire/métabolisme
18.
Am J Case Rep ; 21: e921353, 2020 Mar 15.
Article de Anglais | MEDLINE | ID: mdl-32172274

RÉSUMÉ

BACKGROUND Microscopic tumor foci have been detected incidentally on renal biopsy, including renal cell carcinoma and renomedullary interstitial cell tumor (medullary fibroma). A report is presented of a case of an incidental finding of microscopic renal angiomyolipoma that was diagnosed and completely excised on core needle biopsy. CASE REPORT A 44-year-old woman was referred to our hospital for evaluation of persistent mild proteinuria. Three years previously, she was diagnosed with Cushing's syndrome associated with a right adrenal cortical adenoma, which was successfully treated with unilateral adrenalectomy. At the time of surgery, abdominal computed tomography (CT) showed no renal lesions. During the present admission, a renal biopsy was performed that showed minimal changes in the renal glomeruli and interstitium. Immunofluorescence showed weakly positive staining for IgM in the glomeruli and no dense deposits. A microscopic focus of a predominantly spindle-cell tumor was found in the corticomedullary region. Immunohistochemistry showed positive immunostaining for HMB-45, Melan-A, and alpha-smooth muscle actin (ASMA), which supported a diagnosis of angiomyolipoma. Abdominal ultrasound at one-year follow-up showed no evidence of residual renal tumor. CONCLUSIONS To our knowledge, this is the first reported case of a completely excised incidental microscopic renal angiomyolipoma. This case demonstrated that even when imaging findings are normal, renal biopsy may detect microscopic foci of primary renal tumors.


Sujet(s)
Angiomyolipome/diagnostic , Angiomyolipome/anatomopathologie , Tumeurs du rein/diagnostic , Tumeurs du rein/anatomopathologie , Actines/analyse , Adulte , Angiomyolipome/chirurgie , Marqueurs biologiques tumoraux , Biopsie au trocart , Femelle , Humains , Immunohistochimie , Résultats fortuits , Tumeurs du rein/chirurgie , Antigène MART-1/analyse , Antigènes spécifiques du mélanome/analyse , Antigène gp100 du mélanome
19.
BMC Cardiovasc Disord ; 20(1): 39, 2020 01 30.
Article de Anglais | MEDLINE | ID: mdl-32000687

RÉSUMÉ

BACKGROUND: Although mineral metabolism disorder influences cardiac valvular calcification (CVC), few previous studies have examined the effects of non-calcium-containing and calcium-containing phosphate binders on CVC in maintenance hemodialysis patients. The aim of the present study was to compare the effects of lanthanum carbonate (LC) with calcium carbonate (CC) on the progression of CVC in patients who initiated maintenance hemodialysis and to investigate clinical factors related to CVC. METHODS: The current study included 50 subjects (mean age 65 years, 72% males) from our previous randomized controlled trial (LC group, N = 24; CC group, N = 26). CVC was evaluated as CVC score (CVCS) using echocardiography at baseline and 18 months after initiation of hemodialysis. We compared CVCS and the changes between the two groups. We also analyzed the associations between CVCS and any other clinical factors including arterial plaque score (PS) and serum phosphorus levels. RESULTS: Baseline characteristics of study participants including CVCS were almost comparable between the two groups. At 18 months, there were no significant differences in mineral metabolic markers or CVCS between the two groups, and CVCS were significantly correlated with PS (r = 0.39, p < 0.01). Furthermore, changes in CVCS were significantly correlated with average phosphorus levels (r = 0.36, p < 0.05), which were significantly higher in high serum phosphorus and high PS group compared to low serum phosphorus and low PS group (p < 0.05). CONCLUSIONS: In the present study, there were no significant differences between LC and CC with regard to progression of CVC. However, serum phosphorus levels and arterial plaque seem to be important for the progression and formation of CVC in hemodialysis patients.


Sujet(s)
Calcinose/prévention et contrôle , Carbonate de calcium/usage thérapeutique , Chélateurs/usage thérapeutique , Valvulopathies/prévention et contrôle , Maladies du rein/thérapie , Lanthane/usage thérapeutique , Dialyse rénale , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/sang , Calcinose/sang , Calcinose/imagerie diagnostique , Calcinose/étiologie , Carbonate de calcium/effets indésirables , Chélateurs/effets indésirables , Évolution de la maladie , Femelle , Valvulopathies/sang , Valvulopathies/imagerie diagnostique , Valvulopathies/étiologie , Humains , Maladies du rein/sang , Maladies du rein/complications , Maladies du rein/diagnostic , Lanthane/effets indésirables , Mâle , Adulte d'âge moyen , Phosphore/sang , Essais contrôlés randomisés comme sujet , Dialyse rénale/effets indésirables , Facteurs de risque , Facteurs temps , Résultat thérapeutique
20.
J Nephrol ; 33(4): 795-802, 2020 Aug.
Article de Anglais | MEDLINE | ID: mdl-31919783

RÉSUMÉ

BACKGROUND: Although a previous study has reported the relationship between intact parathyroid hormone (iPTH) and whole parathyroid hormone (wPTH) levels in patients undergoing dialysis, the w/i PTH ratio (whole/intact PTH ratio) among predialysis chronic kidney disease (CKD) patients remains unclear. The present study therefore aimed to examine the relationship between w/i PTH ratio and kidney function and determine other factors affecting the w/i PTH ratio. METHODS: An observational study including 773 predialysis CKD patients was conducted. The correlation between w/i PTH ratio and kidney function, as well as clinical factors at different CKD stages, were assessed using univariate and multivariate analyses. In addition, the relationship between w/i PTH ratio and composite renal outcome [kidney transplantation, dialysis, and 30% decline in estimated glomerular filtration rate (eGFR)] was examined. RESULTS: The w/i PTH ratio decreased as the CKD stage progressed. Patients in each CKD stage (1/2, 3, 4, and 5) had a w/i PTH ratio of 0.85, 0.81, 0.78, and 0.59, respectively. The inflection point in the correlation lines between eGFR and w/i PTH ratio was 24.1 mL/min/1.73 m2. In multivariate analysis, the w/i PTH ratio was significantly correlated with serum calcium levels only in the CKD5 group and with eGFR in the CKD3, CKD4 and CKD5 group. Furthermore, w/i PTH ratio, eGFR, serum phosphate levels, and urinary protein/creatinine ratio were determined to be significant independent predictors for composite renal outcome. CONCLUSIONS: Our study demonstrated that changes in the w/i PTH ratio were associated with kidney function, abnormal mineral metabolism, and renal outcome.


Sujet(s)
Défaillance rénale chronique , Transplantation rénale , Insuffisance rénale chronique , Calcium , Débit de filtration glomérulaire , Humains , Défaillance rénale chronique/métabolisme , Défaillance rénale chronique/thérapie , Hormone parathyroïdienne/métabolisme , Dialyse rénale , Insuffisance rénale chronique/métabolisme , Insuffisance rénale chronique/thérapie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...